DE69330032T2 - Therapeutisches kombinationspräparat enthaltend interferon - Google Patents
Therapeutisches kombinationspräparat enthaltend interferonInfo
- Publication number
- DE69330032T2 DE69330032T2 DE69330032T DE69330032T DE69330032T2 DE 69330032 T2 DE69330032 T2 DE 69330032T2 DE 69330032 T DE69330032 T DE 69330032T DE 69330032 T DE69330032 T DE 69330032T DE 69330032 T2 DE69330032 T2 DE 69330032T2
- Authority
- DE
- Germany
- Prior art keywords
- hepatitis
- interferon
- treatment
- human interferon
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000014150 Interferons Human genes 0.000 title abstract description 42
- 108010050904 Interferons Proteins 0.000 title abstract description 42
- 229940079322 interferon Drugs 0.000 title abstract description 29
- 230000001225 therapeutic effect Effects 0.000 title abstract description 4
- 238000002360 preparation method Methods 0.000 title description 8
- 238000011282 treatment Methods 0.000 claims abstract description 45
- 239000002243 precursor Substances 0.000 claims abstract description 25
- 239000000411 inducer Substances 0.000 claims abstract description 22
- 108010047761 Interferon-alpha Proteins 0.000 claims description 73
- 102000006992 Interferon-alpha Human genes 0.000 claims description 73
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 71
- 229960003180 glutathione Drugs 0.000 claims description 38
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical group CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 34
- 229960004308 acetylcysteine Drugs 0.000 claims description 34
- 208000005176 Hepatitis C Diseases 0.000 claims description 27
- 108010024636 Glutathione Proteins 0.000 claims description 23
- 208000002672 hepatitis B Diseases 0.000 claims description 22
- 208000006454 hepatitis Diseases 0.000 claims description 17
- 208000010710 hepatitis C virus infection Diseases 0.000 claims description 16
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 22
- 229940123457 Free radical scavenger Drugs 0.000 abstract description 8
- 239000002516 radical scavenger Substances 0.000 abstract description 8
- 238000002648 combination therapy Methods 0.000 abstract description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 17
- 108010082126 Alanine transaminase Proteins 0.000 description 17
- 229940047124 interferons Drugs 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- 241000700605 Viruses Species 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 231100000283 hepatitis Toxicity 0.000 description 13
- 241000711549 Hepacivirus C Species 0.000 description 12
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 12
- 150000003254 radicals Chemical class 0.000 description 12
- 208000006154 Chronic hepatitis C Diseases 0.000 description 11
- 210000002381 plasma Anatomy 0.000 description 10
- 230000003612 virological effect Effects 0.000 description 10
- 230000001684 chronic effect Effects 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 230000004044 response Effects 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 5
- 230000036542 oxidative stress Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000007882 cirrhosis Effects 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 108010006088 interferon alfa-n1 Proteins 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 208000005331 Hepatitis D Diseases 0.000 description 2
- 206010019755 Hepatitis chronic active Diseases 0.000 description 2
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 description 2
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 2
- 102100040018 Interferon alpha-2 Human genes 0.000 description 2
- 108010078049 Interferon alpha-2 Proteins 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 102000003996 Interferon-beta Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 208000005252 hepatitis A Diseases 0.000 description 2
- 102000043557 human IFNG Human genes 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 230000000510 mucolytic effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 102000014898 transaminase activity proteins Human genes 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010065051 Acute hepatitis C Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108091028075 Circular RNA Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- IEPRKVQEAMIZSS-UHFFFAOYSA-N Di-Et ester-Fumaric acid Natural products CCOC(=O)C=CC(=O)OCC IEPRKVQEAMIZSS-UHFFFAOYSA-N 0.000 description 1
- IEPRKVQEAMIZSS-WAYWQWQTSA-N Diethyl maleate Chemical compound CCOC(=O)\C=C/C(=O)OCC IEPRKVQEAMIZSS-WAYWQWQTSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000724675 Hepatitis E virus Species 0.000 description 1
- 208000037262 Hepatitis delta Diseases 0.000 description 1
- 241000724709 Hepatitis delta virus Species 0.000 description 1
- 206010019791 Hepatitis post transfusion Diseases 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- KJQFBVYMGADDTQ-CVSPRKDYSA-N L-buthionine-(S,R)-sulfoximine Chemical compound CCCCS(=N)(=O)CC[C@H](N)C(O)=O KJQFBVYMGADDTQ-CVSPRKDYSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000001621 Mucoproteins Human genes 0.000 description 1
- 108010093825 Mucoproteins Proteins 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 208000037621 acute hepatitis C virus infection Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229940124445 corneal wound healing agent Drugs 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 108010042414 interferon gamma-1b Proteins 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 208000012237 paracetamol poisoning Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/34—Trocars; Puncturing needles
- A61B17/3417—Details of tips or shafts, e.g. grooves, expandable, bendable; Multiple coaxial sliding cannulas, e.g. for dilating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/34—Trocars; Puncturing needles
- A61B17/3476—Powered trocars, e.g. electrosurgical cutting, lasers, powered knives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/34—Trocars; Puncturing needles
- A61B17/3494—Trocars; Puncturing needles with safety means for protection against accidental cutting or pricking, e.g. limiting insertion depth, pressure sensors
- A61B17/3496—Protecting sleeves or inner probes; Retractable tips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B18/1487—Trocar-like, i.e. devices producing an enlarged transcutaneous opening
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/32—Surgical cutting instruments
- A61B17/3205—Excision instruments
- A61B17/3207—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions
- A61B17/320725—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions with radially expandable cutting or abrading elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/32—Surgical cutting instruments
- A61B17/3205—Excision instruments
- A61B17/3207—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions
- A61B17/32075—Pullback cutting; combined forward and pullback cutting, e.g. with cutters at both sides of the plaque
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/32—Surgical cutting instruments
- A61B17/3209—Incision instruments
- A61B17/3211—Surgical scalpels, knives; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/34—Trocars; Puncturing needles
- A61B17/3474—Insufflating needles, e.g. Veress needles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00053—Mechanical features of the instrument of device
- A61B2018/00184—Moving parts
- A61B2018/0019—Moving parts vibrating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M13/00—Insufflators for therapeutic or disinfectant purposes, i.e. devices for blowing a gas, powder or vapour into the body
- A61M13/003—Blowing gases other than for carrying powders, e.g. for inflating, dilating or rinsing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Surgery (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Plasma & Fusion (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929226729A GB9226729D0 (en) | 1992-12-22 | 1992-12-22 | Therapeutic combination |
| PCT/GB1993/002600 WO1994014473A1 (en) | 1992-12-22 | 1993-12-20 | Therapeutic combination containing interferon |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69330032D1 DE69330032D1 (de) | 2001-04-19 |
| DE69330032T2 true DE69330032T2 (de) | 2001-09-06 |
Family
ID=10727038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69330032T Expired - Fee Related DE69330032T2 (de) | 1992-12-22 | 1993-12-20 | Therapeutisches kombinationspräparat enthaltend interferon |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US5830455A (en:Method) |
| EP (1) | EP0675730B1 (en:Method) |
| JP (2) | JP2849214B2 (en:Method) |
| KR (1) | KR100309059B1 (en:Method) |
| CN (1) | CN1094642A (en:Method) |
| AT (1) | ATE199643T1 (en:Method) |
| AU (1) | AU680858B2 (en:Method) |
| CA (1) | CA2152389A1 (en:Method) |
| DE (1) | DE69330032T2 (en:Method) |
| ES (1) | ES2156150T3 (en:Method) |
| FR (1) | FR2699407A1 (en:Method) |
| GB (1) | GB9226729D0 (en:Method) |
| HR (1) | HRP931510A2 (en:Method) |
| HU (1) | HUT72965A (en:Method) |
| IL (1) | IL108114A (en:Method) |
| IT (1) | IT1261949B (en:Method) |
| MY (1) | MY141415A (en:Method) |
| NO (1) | NO952469D0 (en:Method) |
| PL (1) | PL309398A1 (en:Method) |
| RU (1) | RU2145235C1 (en:Method) |
| TW (1) | TW286283B (en:Method) |
| WO (1) | WO1994014473A1 (en:Method) |
| YU (1) | YU79393A (en:Method) |
| ZA (1) | ZA939583B (en:Method) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5508031A (en) * | 1986-11-21 | 1996-04-16 | Cetus Oncology Corporation | Method for treating biological damage using a free-radial scavenger and interleukin-2 |
| DE4325547C2 (de) * | 1993-07-29 | 1997-11-27 | Max Planck Gesellschaft | Verwendung von Thiolverbindungen zur Therapie von Hepatitis-_Viren-induzierten Erkrankungen |
| US6020205A (en) * | 1998-04-10 | 2000-02-01 | Immunosciences Lab, Inc. | Determination of intracellular antioxidant levels |
| RU2156134C2 (ru) * | 1998-05-12 | 2000-09-20 | ООО "Формавит" | Биофармацевтический препарат на основе живой культуры bacillus и способ лечения заболевания инфекционной природы |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| MXPA02011691A (es) * | 2000-05-26 | 2004-05-17 | Idenix Cayman Ltd | Metodos y composiciones para el tratamiento de flavivirus y pestivirus. |
| WO2002044717A1 (en) * | 2000-12-01 | 2002-06-06 | Cornell Research Foundation | Animal model for flaviviridae infection |
| US6759061B2 (en) * | 2001-08-31 | 2004-07-06 | Renew Life, Inc. | Liver function improvement formulation |
| RU2242243C2 (ru) * | 2001-09-27 | 2004-12-20 | Вертелецкий Павел Васильевич | Композиции и способы потенцирования терапевтических эффектов интерферонов |
| WO2003026589A2 (en) * | 2001-09-28 | 2003-04-03 | Idenix (Cayman) Limited | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides |
| WO2003043573A2 (en) * | 2001-11-16 | 2003-05-30 | The Uab Research Foundation | Xanthine oxidase inhibition |
| MXPA04012802A (es) | 2002-06-28 | 2005-04-19 | Idenix Cayman Ltd | Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae. |
| KR20050048544A (ko) | 2002-06-28 | 2005-05-24 | 이데닉스 (케이만) 리미티드 | 플라비비리다에 감염 치료용의 변형된 2' 및3'-뉴클레오사이드 프로드럭 |
| US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| CN101172993A (zh) | 2002-06-28 | 2008-05-07 | 埃迪尼克斯(开曼)有限公司 | 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷 |
| JP2004155777A (ja) * | 2002-10-16 | 2004-06-03 | Asahi Kasei Pharma Kk | Ｃ型慢性肝炎治療剤 |
| ES2624353T3 (es) | 2002-11-15 | 2017-07-13 | Idenix Pharmaceuticals Llc | 2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae |
| EP1567172A2 (en) * | 2002-11-29 | 2005-08-31 | GPC Biotech AG | Formulations useful against hepatitis c virus infections |
| RU2005121904A (ru) | 2002-12-12 | 2006-01-20 | Айденикс (Кайман) Лимитед (Ky) | Способ получения 2`-разветвленных нуклеозидов |
| CA2529311A1 (en) * | 2003-03-28 | 2004-10-07 | Pharmasset, Inc. | Compounds for the treatment of flaviviridae infections |
| EP2345658A1 (en) | 2003-05-30 | 2011-07-20 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
| EP1655292B1 (en) * | 2003-07-22 | 2015-04-29 | Kyowa Hakko Bio Co., Ltd | Preventive or therapeutic composition for viral infectious disease |
| WO2005009418A2 (en) | 2003-07-25 | 2005-02-03 | Idenix (Cayman) Limited | Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c |
| WO2005018330A1 (en) * | 2003-08-18 | 2005-03-03 | Pharmasset, Inc. | Dosing regimen for flaviviridae therapy |
| JP2005104852A (ja) * | 2003-09-29 | 2005-04-21 | Kyowa Hakko Kogyo Co Ltd | モービリウィルス感染症の予防または治療用組成物 |
| CN1980657A (zh) | 2004-05-05 | 2007-06-13 | 耶鲁大学 | 新颖的抗病毒赛菊宁黄质类似物 |
| CN101023094B (zh) | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备 |
| JP5001842B2 (ja) | 2004-09-14 | 2012-08-15 | ギリアド ファーマセット エルエルシー | ２’−フルオロ−２’−アルキル−置換又は他の置換されていてもよいリボフラノシルピリミジン類及びプリン類並びにそれらの誘導体の製造 |
| JP4516863B2 (ja) * | 2005-03-11 | 2010-08-04 | 株式会社ケンウッド | 音声合成装置、音声合成方法及びプログラム |
| CU23432B6 (es) | 2005-11-02 | 2009-10-16 | Ct Ingenieria Genetica Biotech | Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras |
| WO2007075876A2 (en) | 2005-12-23 | 2007-07-05 | Idenix Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| TW200946541A (en) * | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| EA019295B1 (ru) | 2008-12-23 | 2014-02-28 | Джилид Фармассет, Ллс. | Соединения пуриновых нуклеозидов и способ их получения |
| CA2748057C (en) | 2008-12-23 | 2018-07-03 | Pharmasset, Inc. | Nucleoside phosphoramidates |
| BRPI0922508A8 (pt) | 2008-12-23 | 2016-01-19 | Pharmasset Inc | Análogos de nucleosídeo |
| TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
| TWI498117B (zh) | 2010-03-31 | 2015-09-01 | Gilead Pharmasset Llc | 核苷氨基磷酸酯 |
| US10838095B2 (en) | 2010-08-05 | 2020-11-17 | Pgs Geophysical As | Wavefield deghosting of seismic data recorded using multiple seismic sources at different water depths |
| US8841275B2 (en) | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| US8809354B2 (en) | 2011-12-31 | 2014-08-19 | Sheikh Riazuddin | 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections |
| JP2016529293A (ja) | 2013-08-27 | 2016-09-23 | ギリアド ファーマセット エルエルシー | ２つの抗ウイルス化合物の組合せ製剤 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1526205A (en) * | 1974-11-07 | 1978-09-27 | Searle & Co | Treatment of interferon-like material |
| US4100150A (en) * | 1975-11-04 | 1978-07-11 | G. D. Searle & Co. | Stabilization of interferon against mechanical stress using thioctic acid |
| US4762705A (en) * | 1981-11-10 | 1988-08-09 | Adolf W. Schwimmer | Cancer therapy with interferon |
| US4636383A (en) * | 1984-08-29 | 1987-01-13 | Schering Corporation | Interferon-cyclaradine combination |
| US4927762A (en) * | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| CH666814A5 (it) * | 1986-07-24 | 1988-08-31 | Inpharzam Int Sa | Composizione farmaceutica idrosolubile contenente n-acetil-cisteina. |
| US4985241A (en) * | 1986-11-21 | 1991-01-15 | Cetus Corporation | Therapeutic combination of free-radical scavenger and tumor necrosis factor |
| CA1321349C (en) * | 1986-11-21 | 1993-08-17 | Robert Zimmerman | Therapeutic combination of free-radical scavenger or metabolic inhibitor and biologically active protein |
| IT1231012B (it) * | 1989-07-27 | 1991-11-08 | Zambon Spa | Composizione farmaceutica per uso orale contenente nac. |
| US5248697A (en) * | 1990-09-20 | 1993-09-28 | Brigham And Women's Hospital | Enhancement of glutathione levels with glutamine |
| ATE134002T1 (de) * | 1990-11-19 | 1996-02-15 | Manz Galvano Technik Gmbh | Sperr- und dränagevorrichtung für tauchtrommeln bei der galvanischen und/oder chemischen oberflächenbehandlung von massenteilen |
| JP2597953B2 (ja) | 1991-12-10 | 1997-04-09 | 大塚製薬株式会社 | 制癌剤 |
-
1992
- 1992-12-22 GB GB929226729A patent/GB9226729D0/en active Pending
-
1993
- 1993-04-12 TW TW082102718A patent/TW286283B/zh active
- 1993-12-20 AU AU57076/94A patent/AU680858B2/en not_active Ceased
- 1993-12-20 RU RU95113492A patent/RU2145235C1/ru active
- 1993-12-20 HU HU9501841A patent/HUT72965A/hu unknown
- 1993-12-20 AT AT94902910T patent/ATE199643T1/de not_active IP Right Cessation
- 1993-12-20 CA CA002152389A patent/CA2152389A1/en not_active Abandoned
- 1993-12-20 WO PCT/GB1993/002600 patent/WO1994014473A1/en not_active Ceased
- 1993-12-20 EP EP94902910A patent/EP0675730B1/en not_active Expired - Lifetime
- 1993-12-20 DE DE69330032T patent/DE69330032T2/de not_active Expired - Fee Related
- 1993-12-20 ES ES94902910T patent/ES2156150T3/es not_active Expired - Lifetime
- 1993-12-20 JP JP6514930A patent/JP2849214B2/ja not_active Expired - Lifetime
- 1993-12-20 YU YU79393A patent/YU79393A/sh unknown
- 1993-12-20 KR KR1019950702659A patent/KR100309059B1/ko not_active Expired - Fee Related
- 1993-12-20 PL PL93309398A patent/PL309398A1/xx unknown
- 1993-12-21 IT ITRM930840A patent/IT1261949B/it active IP Right Grant
- 1993-12-21 JP JP5322685A patent/JPH06234657A/ja active Pending
- 1993-12-21 HR HR931510A patent/HRP931510A2/hr not_active Application Discontinuation
- 1993-12-21 CN CN93121281A patent/CN1094642A/zh active Pending
- 1993-12-21 IL IL10811493A patent/IL108114A/en active IP Right Grant
- 1993-12-21 MY MYPI93002794A patent/MY141415A/en unknown
- 1993-12-21 ZA ZA939583A patent/ZA939583B/xx unknown
- 1993-12-21 FR FR9315349A patent/FR2699407A1/fr active Pending
-
1995
- 1995-06-20 NO NO952469A patent/NO952469D0/no not_active Application Discontinuation
-
1996
- 1996-09-06 US US08/706,645 patent/US5830455A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PL309398A1 (en) | 1995-10-02 |
| MY141415A (en) | 2010-04-30 |
| EP0675730A1 (en) | 1995-10-11 |
| JP2849214B2 (ja) | 1999-01-20 |
| TW286283B (en:Method) | 1996-09-21 |
| HUT72965A (en) | 1996-06-28 |
| CN1094642A (zh) | 1994-11-09 |
| NO952469L (no) | 1995-06-20 |
| ATE199643T1 (de) | 2001-03-15 |
| EP0675730B1 (en) | 2001-03-14 |
| YU79393A (sh) | 1996-10-09 |
| IT1261949B (it) | 1996-06-04 |
| FR2699407A1 (fr) | 1994-06-24 |
| KR100309059B1 (ko) | 2002-06-20 |
| ITRM930840A0 (it) | 1993-12-21 |
| JPH08504799A (ja) | 1996-05-21 |
| HU9501841D0 (en) | 1995-08-28 |
| IL108114A0 (en) | 1994-04-12 |
| RU2145235C1 (ru) | 2000-02-10 |
| HRP931510A2 (en) | 1995-12-31 |
| US5830455A (en) | 1998-11-03 |
| JPH06234657A (ja) | 1994-08-23 |
| IL108114A (en) | 1999-12-31 |
| CA2152389A1 (en) | 1994-07-07 |
| ZA939583B (en) | 1995-05-22 |
| AU680858B2 (en) | 1997-08-14 |
| WO1994014473A1 (en) | 1994-07-07 |
| ES2156150T3 (es) | 2001-06-16 |
| AU5707694A (en) | 1994-07-19 |
| GB9226729D0 (en) | 1993-02-17 |
| DE69330032D1 (de) | 2001-04-19 |
| NO952469D0 (no) | 1995-06-20 |
| ITRM930840A1 (it) | 1995-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69330032T2 (de) | Therapeutisches kombinationspräparat enthaltend interferon | |
| DE69333321T2 (de) | Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten. | |
| DE3876125T2 (de) | Behandlung der menschlichen viralinfektion durch doppelstrang-rna, kombiniert mit viralen inhibitoren. | |
| DE69219782T2 (de) | Verwendung eines thymosins bei der behandlung von hepatitis c | |
| DE69927971T2 (de) | Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c | |
| DE69820247T2 (de) | Polyethylene glycol-interferon alpha konjugate für therapie der infektionen | |
| DE69328558T2 (de) | Pharmazeutisches Präparat zur synergistischen Aktivierung natürlicher Killerzellen | |
| DE69232426T2 (de) | Zusammensetzungen zur behandlung und vorbeugung von krebs | |
| US7678774B2 (en) | Treating severe acute respiratory syndrome | |
| DE69130679T2 (de) | Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation | |
| DE69220821T2 (de) | Verfahren zur Sicherstellung eines angemessenen intrazellulären Glutathionspiegels im Gewebe | |
| EP1699444A2 (de) | Mittel zur hemmung der virusreplikation durch regulation der proteinfaltung | |
| EP0225759A2 (en) | Interferon compositions | |
| DE3780770T2 (de) | Therapeutisches gemisch aus einem faenger von freien radikalen oder einem stoffwechsel-hemmer und einem biologisch aktiven protein. | |
| Degré | Influence of exogenous interferon on the peripheral white blood cell count in mice | |
| JP3631245B2 (ja) | ＤＮＡウイルス感染の治療のための薬物の製造のための膜翅類昆虫（ｈｙｍｅｎｏｐｔｅｒａ）毒の使用 | |
| EP2670420A1 (de) | Antivirales mittel enthaltend rekombinante mistellektine | |
| DE69428112T2 (de) | Verwendung von thymosin zur behandlung von hepatitis c bei patienten, die auf interferongaben nicht ansprechen | |
| DE69332904T2 (de) | Hemmung von hiv-infektion | |
| KR19990082559A (ko) | 천연 사람 α-인터페론으로 구성된 제약학적 조성물 | |
| WO2001070203A2 (de) | Mittel zur behandlung von hepatitis c, enthaltend ukrain | |
| KR970005325B1 (ko) | 에이즈 발병방지, 치료제 및 그 치료용 조성물 | |
| US20060067913A1 (en) | HCV therapy | |
| Macht et al. | Effect of Repeated Injections of Cobra Venom on Blood Chemistry and Morpholoy | |
| Wilson | Platelet regeneration during therapy of acute leukemia with folic acid antagonists. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |